reviewTop 1% cited

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Leukemia · 2007 · Vol. 22(2) · pp. 414–423

Antonio Palumbo✉(Azienda Ospedaliero Universitaria San Giovanni Battista)S. Vincent Rajkumar(Mayo Clinic)Meletios Α. Dimopoulos(National and Kapodistrian University of Athens)Paul G. Richardson(Dana-Farber Cancer Institute)Jesús F. San Miguel(Complejo Hospitalario de Salamanca)Bart Barlogie(University of Arkansas for Medical Sciences)Jean‐Luc Harousseau(Hôtel-Dieu de Paris)Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute)Michèle Cavo(University of Bologna)Maurizio Zangari(University of Arkansas for Medical Sciences)Michel Attal(Hôpital Purpan)Andrew R. BelchStefan Knop(University of Tübingen)D. Joshua(Royal Prince Alfred Hospital)Orhan Sezer(Charité - Universitätsmedizin Berlin)Heinz Ludwig(Wilhelminen Hospital)David H. Vesole(Saint Vincent Health System)Joan Bladé(Universitat de Barcelona)Robert A. Kyle(Mayo Clinic in Arizona)Jan Westin(Lund University)Diane Weber(The University of Texas MD Anderson Cancer Center)Sara Bringhen(Azienda Ospedaliero Universitaria San Giovanni Battista)Rubén Niesvizky(Cornell University)Anders Waage(St Olav's University Hospital)Marie von Lilienfeld‐Toal(St James's University Hospital)Sagar Lonial(Emory University)Gareth J. Morgan(Institute of Cancer Research)Robert Z. Orlowski(University of North Carolina at Chapel Hill)Kazuyuki ShimizuKenneth C. Anderson(Dana-Farber Cancer Institute)Mario Boccadoro(Azienda Ospedaliero Universitaria San Giovanni Battista)Brian G.M. Durie(Cedars-Sinai Medical Center)Pieter Sonneveld(Erasmus MC)M. A. Hussein(Cleveland Clinic)on behalf of the International Myeloma Working Group

View via DOI Publisher page

Venous Thromboembolism Diagnosis and Management Multiple Myeloma Research and Treatments Cancer Treatment and PharmacologyMedicineLenalidomideThalidomideMultiple myelomaInternal medicineWarfarinOncologyPopulationLow molecular weight heparinSurgery

MeSH terms

LenalidomideAntineoplastic AgentsAspirinHeparin, Low-Molecular-WeightHumansMultiple MyelomaPremedicationRisk FactorsThalidomideThrombosisWarfarinRisk AssessmentInternational Normalized RatioVenous Thromboembolism

Citations

835

FWCI

32.75

field-weighted impact

References

109

Percentile

100%

vs. same field & year

Citations per year

Cited by